Table 2:
Antibiotic use†
| Antimicrobial Class | Empiric Antibiotic Therapy (%) |
Definitive Therapy (%) |
Additional Therapy (%) |
Total Exposed (%) |
|---|---|---|---|---|
| Aminoglycoside | 5 (2.2) | 31 (13.8) | 30 (13.3) | 64 (28.4) |
| Aztreonam | 17 (7.6) | 6 (2.7) | 0 (0.0) | 17 (7.6) |
| Cephalosporin | 56 (24.9) | 27 (12.0) | 8 (3.6) | 73 (32.4) |
| Cephalosporin/β-lactamase inhibitor | 3 (1.8) | 9 (4.0) | 0 (0.0) | 9 (4.0) |
| Carbapenem | 60 (26.7) | 94 (41.8) | 25 (11.1) | 135 (60.0) |
| Fluoroquinolone | 18 (8.0) | 31 (13.8) | 8 (3.6) | 47 (20.9) |
| Fosfomycin | 15 (6.7) | 26 (11.6) | 1 (0.4) | 30 (13.3) |
| Other | 12 (5.3) | 32 (14.2) | 8 (3.6) | 43 (19.1) |
| Penicillin/β-lactamase inhibitor | 44 (19.6) | 18 (8.0) | 9 (4.0) | 62 (27.6) |
| Polymyxin | 6 (2.7) | 31 (13.8) | 5 (2.2) | 38 (16.9) |
†
Total number and percent of infections (n=225) in which each class of antibiotics was use. Total exposure refers to the total number of infections for which antibiotic class was used.